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l l
Purpose: To compare differences in the applicability and incidence of postoperative ad-
verse events among stent-grafts used for repair of infrarenal aortic aneurysms.
Methods: An analysis of 6787 patients from the EUROSTAR Registry database was con-
ducted to compare aneurysm morphological features, patient characteristics, and post-
operative events for the AneuRx, EVT/Ancure, Excluder, Stentor, Talent, and Zenith devices
versus the Vanguard device (control) and each other. Annual incidence rates of compli-
cations were determined, and risks were compared using the Cox proportional hazards
analysis.
Results: The annual incidence rates were: device-related endoleak (types I and III) 6%
(range 4%–10%), type II endoleak 5% (range 0.3%–11%), migration 3% (range 0.5%–5%),
kinking 2% (range 1%–5%), occlusion 3% (range 1%–5%), rupture 0.5% (range 0%–1%), and
all-cause mortality 7% (range 5%–8%). After adjustment for factors influencing outcome,
AneuRx, Excluder, Talent, and Zenith devices were associated with a lower risk of migra-
tion, kinking, occlusion, and secondary intervention compared to the Vanguard device.
Significant increased risk for conversion (EVT/Ancure) and reduced risk of aneurysm rup-
ture (AneuRx and Zenith) and all-cause mortality (Excluder) were found compared to the
Vanguard device.
Conclusions: Significant differences exist between stent-grafts of different labels in terms
of applicability and complications during intermediate to long-term follow-up. Since each
stent-graft has its drawbacks, no single label can be identified as the best. It is reassuring
that developments in stent-grafts indeed result in better performance than the early stent-
grafts. However, a single device incorporating all the perceived improvements should still
be pursued.
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Endovascular repair of abdominal aortic an-
eurysm was introduced in the early 1990s as
a minimal access alternative to conventional
repair. The first stent-grafts implanted were
homemade devices1,2 and served to establish
the feasibility of the technique. These proto-
418 RISK-ADJUSTED OUTCOME OF ENDOVASCULAR AAA REPAIR
van Marrewijk et al.
J ENDOVASC THER
2005;12:417–429
types were followed by a range of commer-
cially manufactured devices, which have been
implanted in relatively large numbers of pa-
tients over the past decade.3–9
To be effective, a stent-graft needs to main-
tain fixation, hemodynamic seal, mechanical
integrity, and patency over many years. How-
ever, a stent-graft implanted in an aortic an-
eurysm is subjected to several adverse fac-
tors that tend to compromise these functions.
Several modes of stent-graft failure have
been documented, and the lessons learned
from early experiences led to changes in var-
ious features of many endografts and with-
drawal of some early models.10
Stent-grafts provided by different manufac-
turers differ in their physical properties and
design features. Each stent-graft system has
its own characteristics, upon which the man-
ufacturers claim specific advantages in terms
of applicability and durability. However, no
single device incorporating all the perceived
improvements exists, which is at least in part
due to patent/copyright protection of some of
these design features.
Published comparisons of outcomes with
different stent-graft models are confined to
short and intermediate-term analyses or
small series.11–16 Comparison of several stent-
graft models in large numbers of patients
over mid to long-term follow-up may provide
insights into relative strengths of each device.
The aim of this study was to compare differ-
ent models of endografts in terms of preop-
erative anatomical variables of the aneurysm
and postoperative outcomes. The EUROSTAR
series is ideally suited for such a comparative
assessment because of the range of stent-
graft models included. Comparative analysis
is indeed one of the prime purposes of a vol-
untary multicenter registry of this kind.17 This
article provides an extensive amount of data
to support detailed comparison among the
stent-graft models.
METHODS
EUROSTAR Project
EUROSTAR (European Collaborators on
Stent-graft Techniques for Abdominal Aortic
Aneurysm Repair) project was launched in
1996 in response to the introduction of the
new technique of repairing aortic aneurysms.
The project was designed as a voluntary pan-
European multicenter registry to allow collec-
tion of as much data as possible in as short a
time as possible for expeditious scientific
evaluation of this technique. Registration is
done on an ‘‘intention-to-treat’’ basis, and
data are collected prospectively by means of
case record forms (paper or online format).
Preoperative evaluation, operative details,
and follow-up data are collected. Follow-up
protocol requires patient assessment by con-
trast-enhanced computed tomography (CT) at
1, 3, 6, 12, and 18 months after the operation
and yearly thereafter. The surveillance proto-
col also includes annual plain radiography
and clinical examination. The information is
stored on an Oracle database (Oracle Corpo-
ration, Redwood Shores, CA, USA) for peri-
odic analysis. Patients enrolled in the data-
base received information about this registry
and consented to have their data included in
the study.18,19
This analysis covered patients who re-
ceived a commercially made stent-graft be-
tween January 1994 and August 2004:
AneuRx (Medtronic Vascular, Santa Rosa, CA,
USA), EVT/Ancure (Guidant Indianapolis, IN,
USA), Excluder (W.L. Gore & Associates, Flag-
staff, AZ, USA), Stentor (MinTec, La Ciotat,
France), Talent (Medtronic Vascular), Van-
guard (Boston Scientific, Natick, MA, USA),
and Zenith (Cook, Indianapolis, IN, USA). The
Stentor was regarded as a first-generation de-
vice, the Vanguard and EVT/Ancure as sec-
ond-generation, and all other brands as third-
generation stent-grafts.
Definitions of Outcome Events
Endoleaks, kinking, migration, and occlu-
sion of the stent-graft occurring after the first
postoperative month were included as re-
ported by individual investigators. It is ex-
pected that current recommended reporting
standards are followed for definition and di-
agnosis, but the absence of a central core lab-
oratory facility means that these complica-
tions are not verified.
Device-related (types I and III) and isolated
type II endoleaks were analyzed as separate
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events. Aneurysm growth and shrinkage were
regarded only when the maximum transverse
aneurysm diameter changed at least 8 mm
from the preoperative measurement. Second-
ary interventions included all reinterventions
other than conversion to open repair, which
was regarded as a separate event.
Patient Sample
During the observation period, 6787 pa-
tients (6341 men; mean age 72 years, range
28–100) from 181 hospitals (Appendix) in 19
countries were included in this analysis. The
mean preoperative aneurysm diameter was
58 mm (range 30–145) and the mean duration
of follow-up was 21 months (range 0–108).
The distribution of stent-graft models over
time is given in Table 1. Preoperative anatom-
ical characteristics of the aneurysms and oth-
er baseline patient characteristics are pre-
sented for each stent-graft in Table 2.
Statistical Analyses
The primary aim of the analysis was to
compare patients who were treated by the
different stent-graft models. Preoperative an-
atomical details of the aneurysm were ana-
lyzed to identify differences in the applicabil-
ity of different endograft models. Adverse
events during follow-up were examined to
characterize the performance of different
models. In order to render this comparison
quantitative, annual incidence rates (IRann:
number of events/person-years at risk) for
each complication were calculated for the en-
tire cohort and for each stent-graft model.
Patients were grouped according to the en-
dograft model. Comparisons performed using
Cox proportional hazards modeling are re-
ported as hazard ratios (HR) and 95% confi-
dence intervals. To allow direct comparison
between two different stent-grafts models,
risks of the different complications were cal-
culated comparing each model of stent-graft
against each other model. Thereafter, the risk
quantification of complications was adjusted
for differences in baseline characteristics be-
cause these factors could potentially influ-
ence the observed association. Adjustments
were made in models with the group of pa-
tients who received a Vanguard device as a
control. In each consecutive model, one more
group of the following factors were added to
the prior model: (1) year of operation; (2) age
at operation, gender, and smoking status; (3)
‘‘high risk’’ for operation and general anesthe-
sia, a history of previous laparotomy, and
obesity; (4) preoperative aneurysm morpho-
logical characteristics, including maximum di-
ameter, aneurysm length, aortic neck angu-
lation, neck diameter, etc.; and finally (5)
stent-graft configuration and experience of
the operating team. This stepwise modeling
enabled determination of any influence of the
individual or grouped baseline characteristics
on the risk. Dummy variables were added to
the models to account for missing values.
Comparisons achieving p,0.05 (2-tailed)
were considered to be statistically significant.
All statistical analyses were performed using
SAS software (version 8.0; SAS Institute Inc.,
Cary, NC, USA)
RESULTS
Endoleaks
Device-related endoleaks were observed at
$1 month in 10% (n5673) of the 6787 pa-
tients, within an at-risk period of 10,868 per-
son-years. Overall, the annual incidence rate
was 6.2%. It was highest (IRann: 9.6%) in pa-
tients with a Stentor and lowest (IRann: 4.1%)
in patients with a Zenith device (Table 3). Sta-
tistically significant differences in the risk of
device-related endoleak (types I and III) were
found for Zenith compared to any other stent-
graft except Excluder and for AneuRx, Exclud-
er, and Talent versus EVT/Ancure and Stentor
(Table 4). Compared to Vanguard (Table 5),
the risk of these endoleaks was reduced 35%,
46%, 26%, and 55% in patients with, respec-
tively, an AneuRx (HR: 0.65, p,0.001), Exclud-
er (HR: 0.54, p,0.001), Talent (HR: 0.74,
p50.01), or Zenith (HR: 0.45, p,0.001) stent-
grafts, while it was increased by 1.45 times in
patients with a Stentor device (p50.003).
However, after adjustment for baseline char-
acteristics, statistical significance remained
only for patients with an AneuRx (HR: 0.72,
p50.02) or a Zenith (HR: 0.49, p,0.001) device
compared to those with a Vanguard device.
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TABLE 1
Annual Number of Registered Stent-Graft Implantations
Totals #1995 1996 1997 1998 1999 2000 2001 2002 $2003
AneuRx 999 (15%) — 4 89 265 273 205 90 49 24
EVT/Ancure 176 (3%) 11 10 41 30 34 16 6 23 5
Excluder 808 (12%) — — — 29 90 108 153 190 238
Stentor 308 (5%) 165 143 — — — — — — —
Talent 1579 (23%) — 9 60 101 168 223 282 306 430
Vanguard 929 (14%) — 89 372 304 149 15 — — —
Zenith 1988 (29%) — — — 15 159 317 483 487 527
Totals 6787 176 255 562 744 873 884 1014 1055 1224
l l
The association between Excluder (p50.05)
and Vanguard (p50.07) was of borderline sig-
nificance in the fully adjusted model.
Isolated type II endoleaks occurred in 8%
(n5542) of patients within an at-risk period of
11,203 person-years. The annual incidence
rate was 4.8% overall, ranging from 0.3% in
patients with a Stentor to 10.5% in patients
with an Excluder device (Table 3). The risk of
isolated type II endoleak (Table 4) differed sig-
nificantly for Excluder compared to any other
label except EVT/Ancure, for Stentor versus
any other label, and for Talent compared to
Zenith. The risk was 88% lower in patients
with a Stentor (HR: 0.12, p,0.001), and 1.54
times increased in patients with an Excluder
(p50.004) compared to Vanguard (Table 5).
However, these associations were due to dif-
ferences in baseline characteristics. Statisti-
cally significant reductions in isolated type II
endoleaks appeared in patients with an
AneuRx (HR: 0.71, p50.045), a Talent (HR:
0.45, p,0.001), or a Zenith (HR: 0.59, p50.007)
device versus Vanguard after correction for
year of operation and persisted in the fully ad-
justed model.
Change in Aneurysm Diameter $8 mm
Aneurysm diameter increase occurred in
6% (n5378) of the patients within an at-risk
period of 11,332 person-years. Overall, the
annual incidence rate was 3.3%, ranging from
2.2% in patients with an EVT/Ancure to 4.3%
in patients with a Talent device (Table 3). An-
eurysm growth was found to be statistically
different only between patients with an
AneuRx (HR: 0.68, p50.03) stent-graft com-
pared to patients with a Talent device (Table
4). This remained unchanged after adjusted
analysis with Talent as control (data not
shown). None of the stent-grafts differed from
Vanguard regarding growth of the aneurysm
(Table 5).
Shrinkage of the aneurysm diameter oc-
curred in 5 times as many patients (30%,
n52031) within a much shorter at-risk period
(8931 person-years). The overall annual inci-
dence rate was 22.7%. Shrinkage was ob-
served most often (IRann: 35.0%) in patients
with a Zenith and least often (IRann: 6.6%) in
patients with a Stentor device (Table 3). Sta-
tistically significant differences in the hazard
ratio of shrinkage were found between almost
all stent-graft labels except AneuRx and Ex-
cluder, both versus Vanguard and each other,
and for Talent and Zenith compared to EVT/
Ancure (Table 4). In the unadjusted compari-
son to Vanguard (Table 5), the aneurysm
shrank least often in patients with a Stentor
(HR: 0.49, p,0.001) and more frequently in
patients with EVT/Ancure (HR: 1.41, p50.008),
Talent (HR: 1.36, p,0.001), or Zenith (HR: 1.54,
p,0.001) devices. After adjustment for base-
line characteristics, the associations of EVT/
Ancure, Talent, and Zenith were unchanged.
Migration
Graft migration was observed in 5%
(n5323) of the patients in an at-risk period of
11,459 person-years. The annual incidence
rate, which was 2.8% overall, ranged from
0.5% in patients with an EVT/Ancure to 5.0%
in patients with a Vanguard stent-graft (Table
3). Higher risk of graft migration was found
J ENDOVASC THER
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TABLE 2
Percentage of Preoperative Characteristics per Stent-Graft Label
AneuRx EVT/Ancure Excluder Stentor Talent Vanguard Zenith
Mean follow-up, mo
[range] 24 [0–72] 29 [0–96] 14 [0–60] 51 [0–108] 16 [0–84] 36 [0–96] 15 [0–72]
Aortic neck
Diameter, mm
,20 6 (59) 13 (22) 6 (49) 7 (22) 4 (60) 13 (124) 4 (84)
20–24 64 (641) 70 (123) 69 (557) 34 (105) 42 (666) 67 (619) 47 (940)
$25 20 (200) 13 (23) 22 (175) 7 (22) 49 (770) 16 (149) 45 (904)
Length, mm
,16 14 (144) 9 (15) 10 (81) 8 (24) 16 (248) 8 (78) 20 (388)
16–30 53 (526) 38 (66) 55 (446) 66 (202) 53 (834) 57 (526) 51 (1016)
.30 27 (272) 20 (36) 30 (243) 19 (59) 26 (418) 29 (273) 25 (502)
Angulation present 19 (194) 21 (37) 27 (216) 14 (42) 21 (329) 23 (214) 23 (458)
Aneurysm
Diameter, mm
,50 23 (225) 15 (27) 20 (160) 28 (86) 12 (189) 23 (210) 13 (252)
50–59 43 (427) 47 (83) 48 (384) 39 (121) 42 (667) 44 (406) 43 (845)
$60 32 (318) 36 (63) 31 (248) 28 (87) 43 (684) 33 (303) 43 (849)
Angulation present 9 (86) 11 (20) 12 (96) 3 (8) 11 (169) 12 (114) 11 (227)
Right iliac artery
Diameter, mm
,11 11 (109) 20 (36) 13 (106) 28 (85) 7 (109) 32 (297) 7 (139)
11–15 45 (445) 32 (57) 33 (270) 41 (125) 31 (495) 48 (444) 23 (459)
$16 15 (145) 6 (10) 12 (99) 6 (18) 20 (312) 12 (111) 22 (444)
Angulation present 28 (277) 23 (41) 33 (270) 13 (41) 32 (501) 38 (353) 33 (661)
Left iliac artery
Diameter, mm
,11 13 (131) 19 (34) 15 (121) 30 (92) 7 (113) 33 (309) 6 (126)
11–15 45 (445) 32 (56) 33 (266) 38 (118) 33 (521) 50 (463) 27 (533)
$16 mm 11 (113) 5 (9) 9 (71) 6 (18) 17 (275) 8 (78) 18 (359)
Angulation present 33 (330) 29 (51) 37 (300) 15 (46) 37 (582) 44 (411) 39 (767)
Aneurysm classification
Aortic 62 (615) 47 (83) 75 (606) 34 (106) 65 (1021) 69 (644) 63 (1253)
Aortoiliac 28 (278) 12 (21) 23 (185) 23 (70) 32 (513) 28 (264) 36 (710)
Device configuration
Bifurcated 92 (919) 70 (124) 96 (772) 90 (276) 85 (1344) 96 (890) 89 (1761)
Other 8 (80) 30 (52) 4 (36) 10 (32) 15 (235) 4 (39) 11 (227)
Hospital experience, number of procedures
,60 61 (613) 70 (123) 58 (467) 78 (239) 69 (1093) 75 (701) 47 (932)
$60 39 (386) 30 (53) 42 (341) 22 (69) 31 (486) 25 (228) 53 (1056)
l l
Percentage of patients within the device group (number of patients) unless indicated otherwise.
between AneuRx and Vanguard devices com-
pared to the other stent-grafts and between
Stentor and Talent versus EVT/Ancure, Ex-
cluder, and Zenith (Tables 4 and 5). In the ad-
justed model compared to Vanguard (Table 5),
the significance of the decreased risks of mi-
gration remained, except in patients with a
Stentor or AneuRx device.
Kinking
Stent-graft kinking occurred in 4% (n5257)
of the patients during an at-risk period of
11,387 person-years. Overall, the annual inci-
dence rate of kinking was 2.3%. It was highest
(IRann: 5.0%) for patients with a Vanguard and
lowest (IRann: 0.6%) for patients with an Ex-
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TABLE 3
Annual Incidence Rates of Complications According to Stent-Graft Model
AneuRx
EVT/
Ancure Excluder Stentor Talent Vanguard Zenith Totals
Device-related
endoleak 0.052 (95) 0.086 (31) 0.050 (45) 0.096 (102) 0.066 (127) 0.072 (177) 0.041 (96) 0.062 (673)
Type II
endoleak 0.045 (84) 0.050 (19) 0.105 (89) 0.003 (4) 0.046 (90) 0.037 (95) 0.070 (161) 0.048 (542)
Growth 0.027 (50) 0.022 (9) 0.042 (37) 0.027 (33) 0.043 (84) 0.027 (72) 0.040 (93) 0.033 (378)
Shrinkage 0.203 (311) 0.264 (74) 0.209 (163) 0.066 (71) 0.300 (440) 0.171 (336) 0.350 (636) 0.227 (2031)
Migration 0.043 (81) 0.005 (2) 0.011 (10) 0.031 (38) 0.024 (48) 0.050 (128) 0.007 (16) 0.028 (323)
Kinking 0.011 (21) 0.022 (9) 0.006 (6) 0.039 (46) 0.010 (20) 0.050 (125) 0.012 (30) 0.023 (257)
Occlusion 0.019 (37) 0.033 (13) 0.011 (10) 0.037 (44) 0.023 (46) 0.053 (133) 0.035 (84) 0.032 (367)
Conversion 0.019 (38) 0.054 (23) 0.009 (8) 0.033 (43) 0.021 (44) 0.022 (63) 0.006 (15) 0.020 (234)
Secondary
intervention 0.063 (113) 0.096 (34) 0.035 (32) 0.094 (98) 0.066 (127) 0.107 (245) 0.053 (122) 0.073 (771)
Rupture 0.004 (7) 0.000 (0) 0.001 (1) 0.008 (11) 0.005 (10) 0.008 (23) 0.002 (4) 0.005 (56)
Death 0.067 (132) 0.047 (20) 0.048 (45) 0.058 (75) 0.071 (146) 0.075 (212) 0.075 (185) 0.068 (815)
l l
Data presented as annual incidence rate (number of patients).
cluder stent-graft (Table 3). The risk of graft
kinking differed significantly between third-
generation models (AneuRx, Excluder, Talent,
and Zenith) compared to the early models
(EVT/Ancure, Stentor, and Vanguard; Tables 4
and 5). The risk of kinking in any stent-graft
but Stentor versus Vanguard (Table 5) re-
mained significantly lower after adjustment
for the differences in baseline characteristics
(Table 5).
Occlusion
Stent-graft occlusion was also reported in
5% (n5367) of the patients, though in a short-
er at-risk period (11,316 person-years). The
overall annual incidence rate was 3.2% (range
1.1% for Excluder to 5.3% for Vanguard; Table
3). The risk of graft (limb) occlusion was re-
duced in patients with an Excluder compared
to any other stent-graft and in patients with
an AneuRx or Talent compared to Zenith. All
of these in turn had a lower risk of limb oc-
clusion than Stentor or Vanguard (Tables 4
and 5). Significance of any of the associations
compared to Vanguard (Table 5) remained af-
ter adjustments for baseline characteristics.
Reinterventions
Conversion to open repair was performed
in 3% (n5234) of all patients. Of these, 76 con-
versions were performed within 30 days of
the initial operation. The annual incidence
rate for conversion was 2.0% overall. It was
highest in patients with an EVT/Ancure (5.4%)
and lowest for patients with a Zenith stent-
graft (0.6%; Table 3). Comparison of stent-
grafts showed a significantly lower conver-
sion risk in patients with an Excluder or Zenith
compared to any other device and for AneuRx
or Talent compared to EVT/Ancure and Sten-
tor (Table 4). After adjustments, the risk of
conversion to open repair was 2.32 times
higher in patients with an EVT/Ancure
(p50.02) and 62% lower in patients with a Ze-
nith device (p50.008) compared to Vanguard
(Table 5), but this risk was no longer signifi-
cantly different between Vanguard and Ex-
cluder.
One or more secondary interventions were
necessary in 11% (n5771) of the patients;
these were transfemoral, transabdominal,
and extra-anatomic, respectively, in 625, 59,
and 162 patients. The annual incidence rate
was 7.3% (range from 3.5% for Excluder to
10.7% for Vanguard; Table 3). The risk of these
reinterventions was significantly reduced for
Excluder compared to any other stent-graft,
for Zenith versus any other brand except Ex-
cluder, and for AneuRx or Talent compared to
the early devices (EVT, Stentor, and Vanguard;
Table 4). The reduced risk of reintervention
with a third-generation device (AneuRx, Ex-
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TABLE 5
Unadjusted and Adjusted Hazard Ratios of Outcome Events Compared to Vanguard Stent-Graft
Hazard Ratio (95% Confidence Interval)
AneuRx EVT/Ancure Excluder Stentor Talent Zenith
Type I/III endoleak
Unadjusted 0.65 (0.5–0.8) 1.12 (0.8–1.6) 0.54 (0.4–0.7) 1.45 (1.1–1.9) 0.74 (0.6–0.9) 0.45 (0.4–0.6)
Adjusted 0.72 (0.5–1.0) 1.21 (0.7–2.0) 0.67 (0.4–1.0)#5 0.81 (0.4–1.6)#1 0.75 (0.5–1.0)#1 0.49 (0.3–0.7)
Type II endoleak
Unadjusted 0.94 (0.7–1.3) 1.20 (0.7–2.0) 1.54 (1.2–2.1) 0.12 (0.0–0.3) 0.78 (0.6–1.0) 1.12 (0.9–1.4)
Adjusted 0.71 (0.5–1.0)#1 1.03 (0.6–1.9) 0.86 (0.6–1.3)#1 0.40 (0.1–2.3)#1 0.45 (0.3–0.7) 0.59 (0.4–0.9)#1
Growth
Unadjusted 0.88 (0.6–1.3) 0.78 (0.4–1.6) 1.20 (0.8–1.8) 1.03 (0.7–1.6) 1.30 (0.9–1.8) 1.19 (0.9–1.6)
Adjusted 0.91 (0.6–1.4) 0.96 (0.4–2.1) 1.03 (0.6–1.7) 1.08 (0.4–2.9) 1.35 (0.9–2.0) 1.01 (0.6–1.6)
Shrinkage
Unadjusted 1.02 (0.9–1.2) 1.41 (1.1–1.8) 0.93 (0.8–1.1) 0.49 (0.4–0.6) 1.36 (1.2–1.6) 1.54 (1.3–1.8)
Adjusted 1.03 (0.9–1.2) 1.52 (1.1–2.1) 0.84 (0.7–1.1)#1,4 0.78 (0.5–1.3)#1 1.29 (1.1–1.6)#1,3 1.42 (1.2–1.7)
Migration
Unadjusted 0.91 (0.7–1.2) 0.10 (0.0–0.4) 0.25 (0.1–0.5) 0.60 (0.4–0.9) 0.53 (0.4–0.7) 0.15 (0.1–0.2)
Adjusted 0.92 (0.7–1.3) 0.18 (0.0–0.8) 0.27 (0.1–0.6) 0.61 (0.2–1.5)#1 0.47 (0.3–0.7) 0.13 (0.1–0.2)
Kinking
Unadjusted 0.21 (0.1–0.3) 0.44 (0.2–0.9) 0.12 (0.1–0.3) 0.85 (0.6–1.2) 0.19 (0.1–0.3) 0.23 (0.2–0.3)
Adjusted 0.25 (0.1–0.4) 0.34 (0.1–0.9) 0.17 (0.1–0.4) 0.86 (0.4–2.0) 0.25 (0.1–0.4) 0.36 (0.2–0.7)
Occlusion
Unadjusted 0.32 (0.2–0.5) 0.59 (0.3–1.0) 0.14 (0.1–0.3) 0.78 (0.6–1.1) 0.33 (0.2–0.5) 0.49 (0.4–0.6)
Adjusted 0.39 (0.3–0.6) 0.70 (0.3–1.4) 0.18 (0.1–0.4) 0.49 (0.2–1.1) 0.34 (0.2–0.5) 0.53 (0.3–0.9)
Conversion
Unadjusted 0.83 (0.6–1.2) 2.34 (1.5–3.8) 0.32 (0.2–0.7) 1.47 (1.0–2.2) 0.81 (0.5–1.2) 0.23 (0.1–0.4)
Adjusted 1.15 (0.7–1.8) 2.32 (1.2–4.6) 0.69 (0.3–1.6)#1 0.59 (0.3–1.3) 1.08 (0.7–1.8) 0.38 (0.2–0.8)
Secondary intervention
Unadjusted 0.54 (0.4–0.7) 0.86 (0.6–1.2) 0.26 (0.2–0.4) 0.96 (0.8–1.2) 0.51 (0.4–0.6) 0.40 (0.3–0.5)
Adjusted 0.57 (0.4–0.7) 0.90 (0.6–1.4) 0.29 (0.2–0.5) 0.67 (0.4–1.2) 0.51 (0.4–0.7) 0.40 (0.3–0.5)
Rupture
Unadjusted 0.50 (0.2–1.2) — 0.17 (0.0–1.3) 0.91 (0.4–1.9) 0.72 (0.3–1.5) 0.26 (0.1–0.8)
Adjusted 0.32 (0.1–0.9)#4 — 0.13 (0.0–1.2) 0.34 (0.0–2.7) 0.44 (0.2–1.2) 0.10 (0.0–0.4)
Death
Unadjusted 0.80 (0.6–1.0) 0.60 (0.4–0.9) 0.49 (0.4–0.7) 0.84 (0.6–1.1) 0.75 (0.6–0.9) 0.78 (0.6–1.0)
Adjusted 0.94 (0.7–1.2)#1 0.67 (0.4–1.2)#1 0.62 (0.4–0.9) 0.73 (0.4–1.4) 0.79 (0.6–1.0)#1 0.86 (0.6–1.2)#1
l l
Statistically significant ratios appear in bold type.
Adjusted results include correction for 1: year of operation, 2: demographics, 3: clinical characteristics, 4: vascular
morphology, and 5: stent-graft–related factors.
# Correction level changing the significance of the association.
cluder, Talent, and Zenith) compared to Van-
guard (Table 5) remained after adjustments
for baseline characteristics.
Rupture
Rupture of the treated aneurysm was doc-
umented in 56 (0.8%) of the 6787 patients
within an at-risk period of 11,946 person-
years, giving an overall annual incidence of
rupture of 0.5%. So far, no ruptures have been
reported in patients with an EVT/Ancure de-
vice. The aneurysm rupture rate was highest
(IRann: 0.8%) in patients with a Stentor or Van-
guard device (Table 3). Due to the small num-
bers of ruptures, statistically significant differ-
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ences were found only for Zenith compared
to Stentor (HR: 0.28, p50.04) and Vanguard
(HR: 0.26, p50.01; Tables 4 and 5). The asso-
ciation between Zenith and Vanguard persist-
ed after adjustments. Additionally, a statisti-
cally significant reduced risk of rupture
appeared for the AneuRx (HR: 0.32, p50.04)
device versus Vanguard (Table 5) after adjust-
ment for vascular morphology.
Mortality
A total of 815 (12%) patients died during an
at-risk period of 11,953 person-years. One
hundred and sixty-eight (2.5%) patients died
within 30 days, of which 15 underwent con-
version to open repair. Of the 647 late deaths,
23 (4%) followed a conversion. Overall, the
(all-cause) annual mortality rate was 6.8% and
was highest (IRann: 7.5%) in patients with a Ze-
nith and lowest (IRann: 4.7%) in patients with
an EVT/Ancure stent-graft (Table 3). The risk
of (all-cause) mortality was statistically signif-
icantly lower for Excluder versus any other la-
bel except EVT/Ancure (Table 4). Compared to
Vanguard (Table 5), mortality risk was de-
creased for all labels except Stentor. However,
significantly reduced mortality compared to
Vanguard remained only in patients with an
Excluder (38%) device after adjustment for
baseline characteristics. The same was found
when analyzing the combined risk of rupture
and death or that of rupture, conversion, and
death (data not shown).
DISCUSSION
Although there are several articles reporting
long-term results of endovascular repair with
individual makes of stent-grafts,7,9,19–25 only a
few compared different endograft models.11–
16,26 Based upon small numbers, these studies
identified several factors that potentially influ-
ence outcome. Patient-related risk factors,
such as age and comorbidities, mainly influ-
ence short-term results.19,27 Factors related to
arterial morphology influence short-term suc-
cess as well as long-term outcome. For ex-
ample, adverse anatomical features, such as
an unfavorable aneurysm neck or narrow iliac
arteries, may lead to technical failure at the
initial repair. Progressive changes in arterial
anatomy during follow-up, such as neck dila-
tation or aneurysmal transformation of iliac
landing zones, may compromise stent-graft
function later on.14,15,24,28–30 Physician-related
factors, such as diagnostic insight, judgment
of suitability for treatment, and operating ex-
perience, also influence outcome.31 All of
these factors have been constantly changing
as endovascular repair has evolved, creating
a potential confounding effect upon compar-
ative analyses. The present study hypothe-
sized that (independent) differences exist be-
tween different makes of stent-grafts, which
suggests that there are endograft-related fac-
tors that influence outcome. Therefore, the
statistical methods included staged correction
for these potentially confounding factors. The
results support a conclusion that stent-graft–
related factors do significantly impact out-
come independent of all the other factors.
Adjustment steps for demographic and clin-
ical characteristics brought out only minor
changes for the outcome events studied. On
the other hand, correction for differences in
year of operation or factors of vascular mor-
phology resulted in considerable shifts in the
risks of complications and in the significance
of their associations. Occasionally this was
profound, with a reversal of the direction of
association. This study confirms the findings
of others, as described above, and underlines
the importance of risk adjustment in such
analyses. Unadjusted risk estimations (e.g.,
Kaplan-Meier analyses) do not always pro-
vide a reliable estimation of risks and might
therefore give an unfair comparison between
stent-graft models.
This study also confirms the influence of
device-specific factors upon almost all early
and late complications.10,13–15,19,26,27 The anal-
ysis reproduced the widely recognized differ-
ences in the incidence of type II endoleak with
different stent-graft models.13,26 Additionally,
differences were also observed in relation to
device-related endoleaks between different
endografts, some persisting after risk adjust-
ment. Lower incidences of device-related en-
doleak reflect a combination of maintaining
proximal and distal seal and fixation and also
better modular stability. Changes in aneu-
rysm diameter remain an important marker of
aneurysm exclusion, and device-specific dif-
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ferences have been reported.13,26,28,29 Certain
stent-graft makes (e.g., Zenith) are associated
with shrinkage more than others. The persis-
tence of differences after risk adjustment
(e.g., for endoleak) in this study might sug-
gest an additional role for device compo-
nents, such as fabric, in influencing postop-
erative changes in aneurysm size. It is also
reassuring to note that most of the newer
stent-grafts fare better in this respect com-
pared to earlier generation devices.
Kink resistance and fixation depend upon
structural aspects of a device, and differences
in performance can be expected among stent-
grafts. The value of hooks and barbs in im-
proving fixation has been recognized,10 which
is reflected in this study by the lower risk of
migration with devices that incorporate these
appendages. Devices without hooks or barbs
depend upon columnar strength for fixation.
However, a risk of cephalad migration (with
or without endoleak) exists if the aneurysm
decreases in size. Partially supported devices,
such as EVT/Ancure, have the potential to mi-
grate downward only. Differences in applica-
bility of stent-grafts exist due to different fix-
ation methods, which are reflected by
differences in patient characteristics (anatom-
ical and general) among the stent-graft labels.
Differences in outcome remain even after ad-
justing for these factors.
Primarily unsupported devices (EVT/An-
cure) might be expected to have the highest
incidence of stent-graft limb occlusion13,16,28
because the lack of device support predispos-
es to angulation and kinking, with resulting
stenosis and thrombosis in the graft.32 In con-
trast, this analysis showed that they in fact
fared slightly better than the other first-
generation endografts. This could be due to
the smaller number of patients with an An-
cure stent-graft. However, this finding might
also point to the fact that kink resistance may
not be afforded by the mere presence of a
stent-graft skeleton but is more a function of
the construction of the skeleton.
A high rate of conversion to open repair
was found in patients with an EVT/Ancure de-
vice. This was primarily due to the large num-
ber of conversions for endoleak (including
hook breakage) in the early experience with
this stent-graft, and this observation is not ap-
plicable to the later Ancure device. Signifi-
cantly fewer conversions were performed in
patients with a Zenith device. Zenith also per-
formed better regarding ruptures, as did the
AneuRx device. No ruptures were reported
with EVT/Ancure, but this might be due to the
high number of conversions performed in this
group. On the other hand, all-cause mortality,
as well as the combined risk of rupture and
death or rupture, conversion, and death, was
significantly lower with the Excluder endo-
graft. Although the EUROSTAR cohort re-
mains one of the largest, with 56 reported
ruptures, caution is necessary while drawing
conclusions since the number of ruptures per
device label remains small. Encouraging is
the observation that 41 ruptures occurred
with devices now regarded as obsolete (Sten-
tor, Vanguard, and AneuRx).
Study Limitations
Despite the strengths of EUROSTAR analy-
ses (i.e., large number of patients, multiple
stent-graft makes, and extensive follow-up),
there are some limitations to the study. Lim-
ited data monitoring and the absence of a
core laboratory mean that it is not possible to
ascertain adherence to the reporting stan-
dards by the large number of centers that
contribute to the registry. The effect of this is
quenched by regression to the mean. Incom-
pleteness of data is considered inevitable in a
voluntary registry; however, significant effort
is made to remedy this situation. Incomplete-
ness of follow-up is not expected to have sig-
nificantly influenced this analysis since it was
distributed over the different groups. At the
inception, the registry was primed by retro-
spective registration of baseline information
and early follow-up results for 13% of all cur-
rently registered patients. From 1996 onward,
when prospective patient registration and
data collection was made mandatory, all in-
formation relating to these patients was col-
lected prospectively. Retrospective data was
mostly of patients with a Stentor device; the
influence of this fact upon the analysis is not
measurable but is considered negligible.
Despite extensive risk adjustment, it was
not possible to correct for every factor that
changed during the study period. Manufac-
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turers have incorporated modifications in de-
vice features to individual stent-graft labels.
Suitability criteria for patients have changed.
Also, reporting standards and diagnostic abil-
ities for endoleaks and other complications
have evolved. These factors could not be sep-
arately adjusted for in the analyses. A com-
bined effect of these and possibly other fac-
tors is partly reflected by year of operation,
explaining the considerable shifts in risks it
brought about. However, these factors might
still have had some influence on the results
in a way that is not quantifiable
Vanguard, the largest group of the first and
second-generation devices, was taken as a
control group to evaluate whether enhance-
ments in design features of the other stent-
graft labels indeed translated to improvement
in outcome. The short and midterm results of
the third-generation stent-grafts appear better
compared to the early (and now withdrawn)
stent-grafts after accounting for the differenc-
es in the duration of follow-up. Nevertheless,
third-generation stent-grafts are not immune
to complications. A complete comparison will
not be possible until even longer follow-up
becomes available with the third-generation
devices.
Conclusions
Stent-graft labels differ significantly in
terms of applicability and individual compli-
cations during intermediate and long-term
follow-up periods. The differences in outcome
are persistent after adjustment for important
factors, such as patient characteristics, vas-
cular morphology, and operator experience.
Although no single make of stent-graft
emerges as the best, it is reassuring to note
that the later models of stent-grafts perform
better than the early versions. However, so
far, reduced risk regarding the primary goal
of the intervention—to prevent rupture and
death—was observed only for patients with
the Excluder device. Results of this compara-
tive analysis should be used to pursue a sin-
gle device that combines all perceived im-
provements. Notably, patent protection of
some of these design features might be re-
garded as conflicting with the best interests
of our patients.
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APPENDIX
EUROSTAR participants who contributed pa-
tient data to this study:
Austria: University Hospital, Vienna.
Belgium: ASZ and Onze Lieve Vrouwe Hos-
pital, Aalst; AZ Middelheim, St. Vincentius
Hospital, UIA, Monica Hospital/OLV/Eeuwfee-
stkliniek, and St. Augustinus Hospital, An-
twerpen; AZ St. Lucas/St. Jozef, Assebroek;
Hospital Princesse Paola, Aye; Imelda Hospi-
tal, Bonheiden; AZ Klina, Brasschaat; AZ St.
Jan AV, Brugge; Hospital Erasme, Academic
Hospital VUB, Clinique de l’Europe St. Michel,
CHU Brugmann, and University Hospital St.
Luc, Brussels; CHU, Charleroi; AZ St. Blasius,
Dendermonde; AZ St. Maarten, Duffel; AZ St.
Dimpna, Geel; St. Jan Hospital, AZ St. Lucas,
and University Hospital, Genk; St. Joseph
Hospital, Gilly; Virga Jesse Hospital, Hasselt;
St. Elisabeth, Herenthals; CAZ St. Franciskus
Hospital, Heusden-Zolder; AZ Groenige, Kort-
rijk; University Hospital and Heilig Hart, Leu-
ven; Notre-Dame des Bruyeres, Lie`ge-Che-
nee; Maria Hospital, Lommel; OLV Hospital,
Mechelen; CHM CNDT, Moucron; CHRN, Na-
mur; AZ Heilige Familie, Reet; Stedelijk Hos-
pital and HHR Hart Hospital, Roeselare; St.
Trudo Hospital, St. Truiden; St. Josef Hospital,
Turnhout; St. Augustinus Hospital, Veurne; St,
Josef Hospital, Vilvoorde.
Denmark: Rigshospitalet, Copenhagen; Uni-
versity Hospital, Odense.
France: Hospital Notre Dame, Draguignan;
Clinique Mutaliste des Eaux Claires, Greno-
ble; Hospital for Cardiology, Lille; Hospital
Jeanne d’Arc and Hospital E Herriot, Lyon;
Polyclinic d’Essey, Nancy; Hospital de la De-
fense, Nanterre; Hospital Henri Mondor and
Hospital Broussais, Paris; CHU Hospital
North, St. Etienne; Institut Arnauld Tzanck, St.
Laurant du Var; Hospital Sarrus Teinturier and
Hospital de Rangueil, Toulouse.
Germany: Surgical University Clinic, Bonn;
Augusta Hospital, Du¨sseldorf; Sta¨dtischen Kli-
niken and Sankt Katharinen, Frankfurt; Uni-
versity Hospital, Freiburg; Altona General
Hospital, Hamburg; Henriettenstiftung, Han-
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nover; Klinikum Kempten; Bundeswehrzen-
tral, Koblenz; Park-Krankenhaus, Leipzig; Uni-
versity Hospital, Mainz; Philipps-University,
Marburg; Kliniken Rechts der Isar, Mu¨nchen;
Pius Hospital, Oldenburg; University Hospital,
Ulm.
Greece: University Medical School, Athens.
Ireland: St. James Hospital, Dublin.
Israel: Sheba Medical Centre, Tel Aviv.
Italy: Policlinico Monteluce, Perugia; Ospe-
dale S Giovanni, Rome.
Luxembourg: Centre Hospitalier, Luxem-
bourg.
Monaco: Centre Cardio-Thoracique, Mona-
co.
The Netherlands: Medical Centre, Alkmaar;
Academic Medical Centre, VU, and Onze
Lieve Vrouwe Gasthuis, Amsterdam; Gelre
Hospital, Apeldoorn; Rijnstate, Arnhem; Rei-
nier de Graaf Group, Delft; Medical Centre
Haaglanden Westeinde and Leijenburg Hos-
pital, The Hague; Albert Schweitzer Hospital,
Dordrecht; Catharina Hospital, Eindhoven;
Medisch Spectrum Twente, Enschede; St.
Anna Hospital, Geldrop; Academic Hospital
and Martini Hospital, Groningen; Academic
Hospital, Maastricht; St. Antonius Hospital,
Nieuwegein; CWZ Hospital and Academic
Hospital, Nijmegen; St. Clara Hospital, Dijk-
zicht Hospital, and Franciscus Gasthuis, Rot-
terdam; Elisabeth Hospital and Tweesteden
Hospital, Tilburg; University Medical Centre,
Utrecht; St. Josef Hospital, Veldhoven; Isala
Clinics Sophia, Zwolle.
Norway: Aker University Hospital and Ul-
leval Hospital, Oslo; University Hospital,
Trondheim.
Poland: L’Academie de Medicine, Lublin;
Medical University, MSWiA Hospital, and
Central Military Hospital, Warsaw.
Spain: University Hospital, Ciutat Sanitaria
i Universitaria de Bellvitge, and Hospital de la
Santa Creu i Sant Pau, Barcelona; Hospital de
Gipuzkoa, Donostia San Sebastian; Hospital
Juan Canalejo and Hospital Santa Teresa, La
Corun˜a; Hospital de Leon, Hospital Xeral
Lugo, University Hospital de la Princesa, Hos-
pital Ramon y Cajal, Fundacion Jimenez Diaz,
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